Literature DB >> 11172871

Neuroendocrine, polysomnographic and psychometric observations in healthy subjects at high familial risk for affective disorders: the current state of the 'Munich vulnerability study'.

J C Krieg1, C J Lauer, W Schreiber, S Modell, F Holsboer.   

Abstract

The present article summarizes the main results of the cross-sectional part of the 'Munich Vulnerability Study' in which healthy first-degree relatives of patients with an affective disorder were investigated by assessing their neuroendocrine, polysomnographic and psychometric status. As patients with an acute episode of a major depression, the group of the healthy relatives exhibited signs of a hyperactive hypothalamic-pituitary-adrenocortical system verified by the combined dexamethasone corticotropin-releasing hormone (DEX/CRH) test, as well as a slow wave sleep deficit in the first sleep cycle and an increased amount of rapid eye movements during REM sleep. The psychometric profile of the healthy relatives was characterised by elevated scores on the scales measuring 'Rigidity' and 'Autonomic Lability'. On a single-case level, 32% of the healthy first-degree relatives of patients with an affective disorder exhibited 'depression-like' features or conspicuous findings in at least two of the three (i.e. neuroendocrine, polysomnographic, psychometric) areas assessed. Whether the relatives with the neurobiological and psychometric abnormalities we identified have a higher risk for developing an affective disorder than those without has to be answered by the still ongoing prospective part of the study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172871     DOI: 10.1016/s0165-0327(00)00348-7

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

Review 1.  Increased mortality in depressive disorders: a review.

Authors:  Pim Cuijpers; Robert A Schoevers
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

Review 2.  [Endophenotype--a new concept for biological characterization of psychiatric disorders].

Authors:  A Zobel; W Maier
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

3.  Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression.

Authors:  Ulla Knorr; Maj Vinberg; Marianne Klose; Ulla Feldt-Rasmussen; Linda Hilsted; Anders Gade; Eva Haastrup; Olaf Paulson; Jørn Wetterslev; Christian Gluud; Ulrik Gether; Lars Kessing
Journal:  Trials       Date:  2009-08-11       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.